Myriad RBM HumanMAPs

The Myriad RBM KidneyMAP panels detect early signs of renal damage which is a common problem in drug development programs. Developed in conjunction with the Predictive Safety Testing Consortium, it provides a sensitive and quantitative method to detect the earliest stages of drug-induced kidney injury. This will allow researchers to efficiently prioritize drug compounds and to accelerate decisions on exploratory and clinical testing protocols.

Urine Biomarkers v. 2.0

Click or mouse over biomarkers for more information. Analytes included in this MAP are subject to change.
1. Beta-2-Microglobulin2. Calbindin
3. Clusterin4. Creatinine
5. Cystatin-C6. Kidney Injury Molecule-1
7. Microalbumin8. Neutrophil Gelatinase-Associated Lipocalin
9. Osteopontin10. Vascular Endothelial Growth Factor

Serum/Plasma Biomarkers v. 1.0

1 This assay did not meet performance specifications in EDTA-Plasma and results should be used for information purposes only.

2 This assay did not meet performance specifications in Serum and results should be used for information purposes only.

Intended for Research Use Only.

Urine Serum or plasma Other fluids*
100 µL 50 µL 350 µL
*Cerebrospinal fluid, urine, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.

Bibliography

Kidney Function and Toxicity

There are no Bibliographies for this Therapy Indication

Every Order Starts With a Quote

Thank you for your interest in Myriad RBM's innovative biomarker solutions. Please tell us more about what you would like to order and provide us with your details, so we can get back to you with a quote.